Madrigal Pharmaceuticals is a biopharmaceutical company developing therapeutics for the treatment of cardiovascular-metabolic diseases.
Madrigal Pharmaceuticals has raised $350.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in July 2025.
Madrigal Pharmaceuticals's investors include Blue Owl, Hercules Capital, Bay City Capital.
Madrigal Pharmaceuticals is headquartered in Conshohocken, United States.
Madrigal Pharmaceuticals is a biopharmaceutical company developing therapeutics for the treatment of cardiovascular-metabolic diseases.
Madrigal Pharmaceuticals is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Madrigal Pharmaceuticals — Funding & Investors." VCBacked, July 22, 2025, https://www.vcbacked.co/company/madrigal-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2025). Madrigal Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/madrigal-pharmaceuticals
{{cite web |title=Madrigal Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/madrigal-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated